Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy
Corresponding Author
Scott A. Coon Pharm.D.
Department of Pharmacotherapeutics & Clinical Research, University of South Florida, Taneja College of Pharmacy, Morsani College of Medicine, Tampa, Florida, USA
Correspondence
Scott A. Coon, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 30, Tampa, FL 33612.
Email: [email protected]
Search for more papers by this authorLucas G. Hill Pharm.D.
Division of Pharmacy Practice, The University of Texas at Austin College of Pharmacy, Austin, Texas, USA
Search for more papers by this authorRobert W. Hutchison Pharm.D.
Department of Pharmacy Practice, Texas A&M Irma Lerma Rangel College of Pharmacy, Round Rock, Texas, USA
Search for more papers by this authorLindsay M. Arnold Pharm.D.
Department of Pharmacy Services, St. Elizabeth's Medical Center, Brighton, Massachusetts, USA
Search for more papers by this authorJennie B. Jarrett Pharm.D., MMedEd, FCCP
Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
Search for more papers by this authorAnne R. Ottney Pharm.D.
Department of Pharmacy Practice, Ferris State University, College of Pharmacy, Big Rapids, Michigan, USA
Search for more papers by this authorAlvin B. Oung Pharm.D.
Department of Pharmacy Practice, University of Wyoming School of Pharmacy, Laramie, Wyoming, USA
Search for more papers by this authorNathan A. Painter Pharm.D.
Division of Clinical Pharmacy, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA
Search for more papers by this authorMichael A. Smith Pharm.D.
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA
Search for more papers by this authorPaul M. Stranges Pharm.D.
Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
Search for more papers by this authorTran H. Tran Pharm.D.
Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois, USA
Search for more papers by this authorAmanda R. McFee Winans Pharm.D.
Section of Clinical Pharmacy, Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, New York, USA
Search for more papers by this authorJeffrey P. Bratberg Pharm.D.
Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA
Search for more papers by this authorCorresponding Author
Scott A. Coon Pharm.D.
Department of Pharmacotherapeutics & Clinical Research, University of South Florida, Taneja College of Pharmacy, Morsani College of Medicine, Tampa, Florida, USA
Correspondence
Scott A. Coon, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 30, Tampa, FL 33612.
Email: [email protected]
Search for more papers by this authorLucas G. Hill Pharm.D.
Division of Pharmacy Practice, The University of Texas at Austin College of Pharmacy, Austin, Texas, USA
Search for more papers by this authorRobert W. Hutchison Pharm.D.
Department of Pharmacy Practice, Texas A&M Irma Lerma Rangel College of Pharmacy, Round Rock, Texas, USA
Search for more papers by this authorLindsay M. Arnold Pharm.D.
Department of Pharmacy Services, St. Elizabeth's Medical Center, Brighton, Massachusetts, USA
Search for more papers by this authorJennie B. Jarrett Pharm.D., MMedEd, FCCP
Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
Search for more papers by this authorAnne R. Ottney Pharm.D.
Department of Pharmacy Practice, Ferris State University, College of Pharmacy, Big Rapids, Michigan, USA
Search for more papers by this authorAlvin B. Oung Pharm.D.
Department of Pharmacy Practice, University of Wyoming School of Pharmacy, Laramie, Wyoming, USA
Search for more papers by this authorNathan A. Painter Pharm.D.
Division of Clinical Pharmacy, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA
Search for more papers by this authorMichael A. Smith Pharm.D.
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA
Search for more papers by this authorPaul M. Stranges Pharm.D.
Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
Search for more papers by this authorTran H. Tran Pharm.D.
Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois, USA
Search for more papers by this authorAmanda R. McFee Winans Pharm.D.
Section of Clinical Pharmacy, Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, New York, USA
Search for more papers by this authorJeffrey P. Bratberg Pharm.D.
Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA
Search for more papers by this authorThis paper represents the opinion of the Adult Medicine and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. It does not necessarily represent an official ACCP commentary, guideline, or statement of policy or position.
Abstract
The opioid crisis represents one of the largest failures of our current health care system as it continues to claim lives at an unprecedented rate and has caused a devastating range of preventable morbidity. Although the availability of highly potent synthetic opioids has amplified the urgency of the crisis for patients and communities, this problem has evolved over several decades. Pharmacists are in a position to offer many potential solutions due to their widespread accessibility, extensive drug knowledge, and integration into various health care settings. This opinion paper challenges the status quo by calling on all pharmacists to embrace evidence-based opioid stewardship and harm reduction practices, contribute to the medical management of opioid use disorder, and address the misconceptions and prejudices that serve as barriers to effective, compassionate patient care. Regardless of practice setting or available resources, pharmacists can take deliberate and impactful steps to address the opioid crisis. Some pharmacists may be positioned to implement innovative and far-reaching pharmacist-led clinical services, while others may simply begin with careful consideration of the language they use when speaking to and about patients with substance use disorders. To optimize patient outcomes, the ineffective laws, regulations, and policies that negatively impact pain and addiction care must be addressed so that evidence-based solutions can be widely disseminated. Pharmacists must aggressively advocate for the removal of barriers preventing high-level clinical practice or policies that perpetuate patient harm and abandonment. Finally, there must be support for continued research on pain and opioid use disorder treatments and services, as well as the impacts of harm reduction practices and pharmacist-led clinical services, so that resources can be allocated effectively.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
- 1Comerci G, Katzman J, Duhigg D. Controlling the swing of the opioid pendulum. N Engl J Med. 2018; 378(8): 691–693.
- 2Baker DW. History of the Joint Commission's pain standards: Lessons for today's prescription opioid epidemic. JAMA. 2017; 317(11): 1117–1118.
- 3Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363(21): 1981–1985.
- 4Schuchat A, Houry D, Guy GP. New data on opioid use and prescribing in the United States. JAMA. 2017; 318(5): 425–426.
- 5Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018; 67(5152): 1419–1427.
- 6Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annu Rev Public Health. 2015; 36: 559–574.
- 7Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016; 64(50–51): 1378–1382.
- 8Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016; 65(1): 1–49.
- 9 Centers for Disease Control and Prevention. Quality improvement and care coordination: Implementing the CDC guideline for prescribing opioids for chronic pain. Atlanta, GA: National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention, 2018 [cited 2019 Nov]. Available from: https://www.cdc.gov/drugoverdose/pdf/prescribing/CDC-DUIP-QualityImprovementAndCareCoordination-508.pdf.
- 10Meara E, Horwitz JR, Powell W, et al. State legal restrictions and prescription-opioid use among disabled adults. N Engl J Med. 2016; 375(1): 44–53.
- 11Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019; 380(23): 2246–2255.
- 12Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64(23): 631–635.
- 13Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over-the-counter status increase pharmacy sales? Health Serv Res. 2019; 54(4): 764–772.
- 14Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. N Engl J Med. 2019; 380(1): 71–79.
- 15Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: A consensus panel report. Pain Med. 2019; 20(4): 724–735.
- 16Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020; 368: m283. https://www.bmj.com/content/bmj/368/bmj.m283.full.pdf
- 17Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019; 380(24): 2285–2287.
- 18Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020; 69(11): 290–297.
- 19Hempstead K, Phillips J. Divergence in recent trends in deaths from intentional and unintentional poisoning. Health Aff. 2019; 38(1): 29–35.
- 20Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016; 165(4): 245–252.
- 21Sandbrink F, Uppal R. The time for opioid stewardship is now. Jt Comm J Qual Patient Saf. 2019; 45(1): 1–2.
- 22Coffin P, Banta-Green C. The dueling obligations of opioid stewardship. Ann Intern Med. 2014; 161(4): 307–308.
- 23Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018; 108(10): 1394–1400.
- 24 Harm Reduction Coalition. Principles of harm reduction. Available from: http://harmreduction.org/about-us/principles-of-harm-reduction/
- 25Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015; 105(8): e55–e63.
- 26Bratberg JP, Smothers ZPW, Collins K, Erstad B, Ruiz Veve J, Muzyk AJ. Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles. J Am Coll Clin Pharm. 2020; 3(2): 478–484.
- 27 Adapt Pharma, Inc. NARCAN® (naloxone hydrochloride) nasal spray. Radnor, PA: Adapt Pharma, Inc., 2015.
- 28 IBM Micromedex®. Naloxone. DRUGDEX®. Greenwood Village, CO: Truven Health Analytics, 2018 [cited 2019 Aug]. Available from: http://www.micromedexsolutions.com/.
- 29Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M, Kelley G. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther. 2015; 4(1): 89–105.
- 30Eggleston W, Podolak C, Sullivan RW, Pacelli L, Keenan M, Wojcik S. A randomized usability assessment of simulated naloxone administration by community members. Addiction. 2018; 113(12): 2300–2304.
- 31Eggleston W, Calleo V, Kim M, Wojcik S. Naloxone administration by untrained community members. Pharmacotherapy. 2020; 40(1): 84–88.
- 32Tippey KG, Yovanoff M, LS MG, Sneeringer P. Comparative human factors evaluation of two nasal naloxone administration devices: NARCAN® nasal spray and naloxone prefilled syringe with nasal atomizer. Pain Ther. 2019; 8(1): 89–98. https://doi.org/10.1007/s40122-019-0118-0.
- 33Gertner AK, Domino ME, Davis CS. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. Drug Alcohol Depend. 2018; 190: 37–41.
- 34Han JK, Hill LG, Koenig ME, Das N. Naloxone counseling for harm reduction and patient engagement. Fam Med. 2017; 49(9): 730–733.
- 35Katzman JG, Takeda MY, Greenberg N, et al. Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program. JAMA Netw Open. 2020; 3(2):e200117.
- 36 American Foundation for AIDS Research. 2017. Syringe service programs and the opioid epidemic. Available from: www.amfar.org/ssp-opioid-epidemic/
- 37Behar E, Rowe C, Santos G-M, Murphy S, Coffin PO. Primary care patient experience with naloxone prescription. Ann Fam Med. 2016; 14(5): 431–436.
- 38Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review. Prev Med. 2018; 114: 79–87.
- 39Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. JAMA Netw Open. 2019; 2(5):e193209.
- 40Jones CM, Compton W, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving prescription opioids in the Medicare part D program, United States, 2016–2017. JAMA. 2019; 322(5): 462–464.
- 41Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. Association of naloxone coprescription laws with naloxone prescription dispensing in the United States. JAMA Netw Open. 2019; 2(6):e196215.
- 42Green TC, Davis C, Xuan Z, Walley AY, Bratberg J. Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014–2018. Am J Public Health. 2020; 110(6): 881–887.
- 43 U.S. Food and Drug Administration. FDA Requiring Labeling Changes for Opioid Pain Medicines, Opioid Use Disorder Medicines Regarding Naloxone. 2020 [cited 2020 July]. Available from: https://www.fda.gov/news-events/press-announcements/fda-requiring-labeling-changes-opioid-pain-medicines-opioid-use-disorder-medicines-regarding.
- 44McClellan C, Lambdin BH, Ali MM, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018; 86: 90–95.
- 45Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011–2017. Drug Alcohol Depend. 2018; 191: 361–364.
- 46Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018; 189: 37–41.
- 47Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019; 179(6): 805–811.
- 48Puzantian T, Gasper JJ. Provision of naloxone without a prescription by california pharmacists 2 years after legislation implementation. JAMA. 2018; 320(18): 1933–1934.
- 49Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 2018; 320(18): 1934–1937.
- 50Hill LG, Reveles KR, Evoy KE. State-level approaches to expanding pharmacists' authority to dispense naloxone may affect accessibility. JAMA Intern Med. 2019; 179(10): 1442–1443.
- 51Palombi L, Hawthorne AN, Lunos S, Melgaard K, Dahly A, Blue H. Community pharmacist utilization of legislation that allows impact on the opioid crisis in the state of Minnesota: A mixed-methods approach. J Pharm Pract. 2019; 14:897190019841747.
- 52Lai Joyce Chun K, Olsen A, Taing M-W, et al. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. Res Social Adm Pharm. 2019; 15(8): 1014–1020.
- 53Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. J Am Pharm Assoc. 2020; 60(1): 81–86.
- 54Abd-Elsayed A, Albert CA, Fischer M, Anderson B. Naloxone academic detailing: Role of community outreach teaching. Curr Pain Headache Rep. 2018; 22(11): 72.
- 55Devries J, Rafie S, Polston G. Implementing an overdose education and naloxone distribution program in a health system. J Am Pharm Assoc. 2017; 57(2S): S154–S160.
- 56Bounthavong M, Harvey MA, Wells DL, et al. Trends in naloxone prescriptions prescribed after implementation of a national academic detailing service in the veterans health administration: A preliminary analysis. J Am Pharm Assoc. 2017; 57(2S): S68–S72.
- 57Strand MA, Eukel H, Frenzel O, Skoy E, Steig J, Werremeyer A. Program evaluation of the opioid and naloxone education (ONE Rx) program using the RE-AIM model. Res Social Adm Pharm. 2020; 16(9): 1248–1254.
- 58Gunn AH, Smothers ZPW, Schramm-Sapyta N, Freiermuth CE, MacEachern M, Muzyk AJ. The emergency department as an opportunity for naloxone distribution. West J Emerg Med. 2018; 19(6): 1036–1042.
- 59Sexton SM, Armstrong A, Gatton O, Rhodes LA, Marciniak MW. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy. J Am Pharm Assoc. 2019; 59(4S): S95–S100.
- 60Griffin S, Wishart B, Bricker K, Luebchow A. Impact of a pharmacist-driven intervention on the outpatient dispensing of naloxone. J Am Pharm Assoc. 2019; 59(4S): S161–S166.
- 61Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. Health Aff. 2016; 35: 832–837.
- 62Stopka TJ, Donahue A, Hutcheson M, Green TC. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc. 2017; 57(2S): S34–S44.
- 63Teshale EH, Asher A, Aslam MV, et al. Estimated cost of comprehensive syringe service program in the United States. PLoS One. 2019; 14(4):e0216205.
- 64Broz D, Zibbell J, Foote C, et al. Multiple injections per injection episode: High-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana. Int J Drug Policy. 2018; 52: 97–101.
- 65 Centers for Disease Control and Prevention. Managing HIV and hepatitis c outbreaks among people who inject drugs: A guide for state and local health departments. 2019 [cited 2019 Sept]. Available from: https://www.cdc.gov/hiv/pdf/programresources/guidance/cluster-outbreak/cdc-hiv-hcv-pwid-guide.pdf
- 66Abdul-Quader AS, Feelemyer J, Modi S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. AIDS Behav. 2013; 17(9): 2878–2892.
- 67Levine H, Bartholomew TS, Rea-Wilson V, et al. Syringe disposal among people who inject drugs before and after the implementation of a syringe services program. Drug Alcohol Depend. 2019; 202: 13–17.
- 68Adams JM. Making the case for syringe services programs. Public Health Rep. 2020; 135(1_suppl): 10S–12S.
- 69Sherman SG, Schneider KE, Park JN, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019; 195: 148–155.
- 70 Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United State—2017 update clinical practice guideline. 2017 [cited 2020 March]. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
- 71Matheson C, Bond CM, Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health. 2007; 29(4): 350–357.
- 72Kennedy-Hendricks A, Gielen A, McDonald E, McGinty EE, Shields W, Barry CL. Medication sharing, storage, and disposal practices for opioid medications among US adults. JAMA Intern Med. 2016; 176(7): 1027–1029.
- 73 Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2018 national survey on drug use and health (HHS publication no. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2019 [cited 2020 Mar]. Available from: https://www.samhsa.gov/data/.
- 74Jones CM, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use United States, 2008–2011. JAMA Intern Med. 2014; 174(5): 802–803.
- 75Maughan BC, Hersh EV, Shofer FS, et al. Unused opioid analgesics and drug disposal following outpatient dental surgery: A randomized controlled trial. Drug Alcohol Depend. 2016; 168: 328–334.
- 76Varisco TJ, Fleming ML, Bapat SS, Wanat MA, Thornton D. Health care practitioner counseling encourages disposal of unused opioid medications. J Am Pharm Assoc. 2019; 59(6): 809–815.e5.
- 77Hasak JM, Roth Bettlach CL, Santosa KB, Larson EL, Stroud J, Mackinnon SE. Empowering post-surgical patients to improve opioid disposal: A before and after quality improvement study. J Am Coll Surg. 2018; 226(3): 235–240.e3.
- 78Gray J, Hagemeier N, Brooks B, Alamian A. Prescription disposal practices: A 2-year ecological study of drug drop box donations in appalachia. Am J Public Health. 2015; 105(9): e89–e94.
- 79Conn J. Summit County group distributes 60,000 disposal pouches for prescription drugs. 2018 [cited 2019 Aug]. Available from: https://www.cleveland.com/akron/2018/08/summit_county_community_partne.html
- 80 Title 40 Code of Federal Regulations. Section 266.505. 2019. Available from: https://www.federalregister.gov/d/2019-01298/page-5819
- 81 Drug Enforcement Administration. Disposal of controlled substances; Final Rule, 21 C.F.R. Parts 1300, 1301, 1304, et al. 2014.
- 82Pedersen CA, Schneider PJ, Ganio MC, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education-2018. Am J Health-Syst Pharm. 2019; 76(14): 1038–1058.
- 83Andrawis M, Ellison LTCC, Riddle S, et al. Recommended quality measures for health-system pharmacy: 2019 update from the Pharmacy Accountability Measures Work Group. Am J Health-Syst Pharm. 2019; 76(12): 874–887.
- 84Tolba R, Meselhy E, Guerra CE. The opioid epidemic and pain medicine specialists: Where to begin and what is next? Ochsner J. 2018; 18(1): 20–22.
- 85Weiner SG, Price CN, Atalay AJ, et al. A health system-wide initiative to decrease opioid-related morbidity and mortality. Jt Comm J Qual Patient Saf. 2019; 45(1): 3–13.
- 86 Committee on Evidence-Based Clinical Practice Guidelines for Prescribing Opioids for Acute Pain, Board on Health Care Services, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Framing opioid prescribing guidelines for acute pain: Developing the evidence. Washington, DC: National Academies Press, 2019 [cited 2019 Dec 20]. Available from: https://www.nap.edu/catalog/25555.
- 87Delgado MK, Shofer FS, Patel MS, et al. Association between electronic medical record implementation of default opioid prescription quantities and prescribing behavior in two emergency departments. J Gen Intern Med. 2018; 33(4): 409–411.
- 88Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med. 2014; 12(6): 573–576.
- 89Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med. 2015; 162(4): 276–286.
- 90Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: A retrospective cohort study. Arch Intern Med. 2012; 172(5): 425–430.
- 91Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine. 2007; 32(19): 2127–2132.
- 92Baldini A, Von Korff M, Lin EHB. A review of potential adverse effects of long-term opioid therapy: A practitioner's guide. Prim Care Companion CNS Disord. 2012; 14(3): PCC.11m01326.
- 93Chua K-P, Brummett CM, Waljee JF. Opioid prescribing limits for acute pain: Potential problems with design and implementation. JAMA. 2019; 321(7): 643–644.
- 94 The U.S. Department of Health and Human Services Working Group on Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. 2019 [cited 2020 Mar]. Available from: https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf
- 95Darnall BD, Juurlink D, Kerns RD, et al. International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med. 2019; 20(3): 429–433.
- 96Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. Ann Intern Med. 2017; 167(3): 181–191.
- 97Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010; 152(11): 712–720.
- 98Tobin DG, Keough Forte K, Johnson MGS. Breaking the pain contract: A better controlled-substance agreement for patients on chronic opioid therapy. Cleve Clin J Med. 2016; 83(11): 827–835.
- 99Starrels JL, Wu B, Peyser D, et al. It made my life a little easier: primary care providers' beliefs and attitudes about using opioid treatment agreements. J Opioid Manag. 2014; 10(2): 95–102.
- 100 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Abuse-deterrent opioids—Evaluation and labeling guidance for industry. 2015 [cited 2019 Oct]. Available from: https://www.fda.gov/files/drugs/published/Abuse-Deterrent-Opioids-Evaluation-and-Labeling.pdf
- 101Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013; 14(4): 351–358.
- 102Becker WC, Fiellin DA. Abuse-deterrent opioid formulations—Putting the potential benefits into perspective. N Engl J Med. 2017; 376(22): 2103–2105.
- 103Kumar VM, Agboola F, Synnott PG, et al. Impact of abuse deterrent formulations of opioids in patients with chronic pain in the United States: A cost-effectiveness model. Value Health. 2019; 22(4): 416–422.
- 104Litman RS, Pagán OH, Cicero TJ. Abuse-deterrent opioid formulations. Anesthesiology. 2018; 128(5): 1015–1026.
- 105 Institute for Clinical and Economic Review. Abuse-deterrent formulations of opioids: Effectiveness and value. 2017 [cited 2020 Mar]. Available from: https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_ADF_Final_Report_08_08_17.pdf
- 106Bao Y, Pan Y, Taylor A, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff. 2016; 35(6): 1045–1051.
- 107Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3): 434–442.
- 108Cochran G, Lo-Ciganic W-H, Gellad WF, et al. Prescription opioid quality measures applied among Pennsylvania Medicaid enrollees. J Manag Care Spec Pharm. 2018; 24(9): 875–885.
- 109Fink DS, Schleimer JP, Sarvet A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review. Ann Intern Med. 2018; 168(11): 783–790. https://doi.org/10.7326/M17-3074.
- 110Brushwood, DB. Unauthorized police access to PDMP data. Pharmacy Today. 2013 [cited 2019 Dec]. Available from: https://www.pharmacytoday.org/article/S1042-0991(15)31271-8/fulltext
- 111 US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for unhealthy drug use: US preventive services task force recommendation statement. JAMA. 2020; 323(22): 2301–2309.
- 112Kulesza M, Ramsey S, Brown R, Larimer M. Stigma among individuals with substance use disorders: Does it predict substance use, and does it diminish with treatment? J Addict Behav Ther Rehabil. 2014; 3(1): 1000115.
- 113 Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration Center for Integrated Health Solutions. SBIRT: Screening, brief intervention, and referral to treatment: Opportunities for implementation and points for consideration. 2011 [cited 2019 Aug]. Available from: https://www.integration.samhsa.gov/sbirt_issue_brief.pdf
- 114Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. Drug Alcohol Depend. 2009; 99(1–3): 280–295.
- 115Gormican EK, Hussein ZS. SBIRT (Screening, Brief Intervention, and Referral to Treatment) among trauma patients: A review of the inpatient process and patient experience. J Trauma Nurs. 2017; 24(1): 42–45.
- 116Pringle JL, Kelley DK, Kearney SM, et al. Screening, brief intervention, and referral to treatment in the emergency department: An examination of health care utilization and costs. Med Care. 2018; 56(2): 146–152.
- 117Saitz R, Palfai TPA, Cheng DM, et al. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014; 312(5): 502–513.
- 118Bogenschutz MP, Donovan DM, Mandler RN, et al. Brief intervention for patients with problematic drug use presenting in emergency departments: A randomized clinical trial. JAMA Intern Med. 2014; 174(11): 1736–1745.
- 119Lindley B, Cox N, Cochran G. Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: A review. Integr Pharm Res Pract. 2019; 8: 85–96.
- 120Cochran G, Field C, Karp J, et al. A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial. J Am Pharm Assoc. 2018; 58(4): 395–403.
- 121Shonesy BC, Williams D, Simmons D, Dorval E, Gitlow S, Gustin RM. Screening, brief intervention, and referral to treatment in a retail pharmacy setting: The pharmacist's role in identifying and addressing risk of substance use disorder. J Addict Med. 2019; 13(5): 403–407.
- 122 Alliance for Addiction Payment Reform. Addiction recovery medical home alternative payment model. 2019 [cited 2020 Jun]. Available from: https://www.incentivizerecovery.org/
- 123Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019; 197: 78–82.
- 124Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015; 9(5): 358–367.
- 125Larochelle MR, Bernstein R, Bernson D, et al. Touchpoints—Opportunities to predict and prevent opioid overdose: A cohort study. Drug Alcohol Depend. 2019; 204: 107537.
- 126 Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (N-SSATS): 2017. Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018 [cited 2020 Mar]. Available from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/2017_NSSATS.pdf.
- 127 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for opioid use disorder save lives. Washington, DC: National Academies Press, 2019 [cited 2019 Aug]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538936/.
- 128 Center for Behavioral Health Statistics and Quality. 2017 National survey on drug use and health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018 [cited 2019 Sept]. Available from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2017/NSDUHDetailedTabs2017.pdf.
- 129Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020; 3(2):e1920622.
- 130Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: j1550.
- 131Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: The international experience. Clin Infect Dis. 2006; 43((suppl 4)): S197–S215.
- 132Winograd RP, Wood CA, Stringfellow EJ, et al. Implementation and evaluation of Missouri's medication first treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2020; 108: 55–64.
- 133Korthuis PT, McCarty D, Weimer M, et al. Primary care-based models for the treatment of opioid use disorder: A scoping review. Ann Intern Med. 2017; 166(4): 268–278.
- 134Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What actually works? A systematic review. PLoS One. 2017; 12(10):e0186315.
- 135Hser Y-I, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016; 111(4): 695–705.
- 136Clark RE, Baxter JD, Aweh G, O'Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015; 57: 75–80.
- 137Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet. 2003; 361(9358): 662–668.
- 138Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; 2:CD002207.
- 139Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA. 2008; 300(17): 2003–2011.
- 140Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiat. 2018; 75(4): 405–407.
- 141Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. Lancet. 2018; 391(10118): 309–318.
- 142Murphy SM, McCollister KE, Leff JA, et al. Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Ann Intern Med. 2019; 170(2): 90–98.
- 143Agrawal A, Lynskey MT. Are there genetic influences on addiction: Evidence from family, adoption and twin studies. Addiction. 2008; 103(7): 1069–1081.
- 144Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005; 45(1): 23–32.
- 145Lo-Ciganic W-H, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016; 111(5): 892–902.
- 146Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Aff. 2015; 34(6): 1028–1034.
- 147 H.R. 2482—116th Congress: Mainstreaming Addiction Treatment Act of 2019. 2019 [cited 2020 March]. Available from: https://www.govtrack.us/congress/bills/116/hr2482
- 148Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019; 114(3): 471–482.
- 149Parrino M. Using medication assisted treatment to treat opioid use disorder: Learning from past experience to guide policy. New York: American Association for the Treatment of Opioid Dependence, Inc. (AATOD), 2019 [cited 2020 March]. Available from: http://www.aatod.org/wp-content/uploads/2019/02/2019-Policy-Paper.pdf.
- 150Stoller KB, Ann MC, Schorr A. Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. 2016 [cited 2019 Aug]. Available from: http://www.aatod.org/wp-content/uploads/2016/07/2nd-Whitepaper-.pdf
- 151Rawson RA. Vermont hub-and-spoke model of care for opioid use disorders: An evaluation. 2017 [cited 2020 Mar]. Available from: https://www.healthvermont.gov/sites/default/files/documents/pdf/ADAP_Hub_and_Spoke_Evaluation_2017_1.pdf
- 152Rawson RA, Rieckmann T, Cousins S, McCann M, Pearce R. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. Prev Med. 2019; 27: 105785.
- 153Luli AJ, Bounthavong M, Watanabe JH. Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. J Am Pharm Assoc. 2020; 60(2): 297–303.
- 154D'Onofrio G, Chawarski MC, O'Connor PG, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention. J Gen Intern Med. 2017; 32(6): 660–666.
- 155Kaucher KA, Caruso EH, Sungar G, et al. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. Am J Emerg Med. 2019; 30: 158373.
- 156Englander H, Dobbertin K, Lind BK, et al. Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: A propensity-matched analysis. J Gen Intern Med. 2019; 34(12): 2796–2803.
- 157Priest KC, McCarty D. Role of the hospital in the 21st century opioid overdose epidemic: The addiction medicine consult service. J Addict Med. 2019; 13(2): 104–112.
- 158Wen H, Druss BG, Cummings JR. Effect of Medicaid expansions on health insurance coverage and access to care among low-income adults with behavioral health conditions. Health Serv Res. 2015; 50(6): 1787–1809.
- 159 ASHP. Statement on the pharmacist's role in substance abuse prevention, education, and assistance. Am J Health-Syst Pharm. 2016; 73(9): e267–e270.
- 160Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder—And its treatment. JAMA. 2014; 311(14): 1393–1394.
- 161Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016; 316(11): 1211–1212.
- 162Hutchinson E, Catlin M, Andrilla CHA, Baldwin L-M, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014; 12(2): 128–133.
- 163Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2002; 4(2):CD002209. https://doi.org/10.1002/14651858.CD002209
- 164Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011; 68(12): 1238–1246.
- 165Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017; 15(4): 359–362.
- 166McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284(13): 1689–1695.
- 167Duffy P, Mackridge AJ. Use and diversion of illicit methadone—Under what circumstances does it occur, and potential risks associated with continued use of other substances. J Subst Use. 2014; 19(1–2): 48–55.
- 168Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010; 39(1): 41–50.
- 169Mark TL, Parish W, Zarkin GA. Association between Medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare part D plans. JAMA. 2019; 322(2): 166–167.
- 170Saloner B, Levin J, Chang H-Y, Jones C, Alexander GC. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the affordable care act Medicaid expansion. JAMA Netw Open. 2018; 1(4):e181588.
- 171DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc. 2015; 55(2): 187–192.
- 172 Drug Enforcement Administration. Mid-level practitioners authorization by state. 2019 [cited 2019 Oct]. Available from: https://www.deadiversion.usdoj.gov/drugreg/practioners/mlp_by_state.pdf
- 173 California Health & Safety Code. Article 2. Treatment of addicts for addiction. Section 11215. 1995.
- 174 California State Board of Pharmacy. The script: Board adopts policy on pharmacists and MAT. 2019 [cited 2019 Sept]. Available from: https://www.pharmacy.ca.gov/publications/19_mar_script.pdf
- 175McBournie A, Duncan A, Connolly E, Rising J. Methadone barriers persist, despite decades of evidence. Health Affairs Blog. 2019 [cited 2020 March]. Available from: https://www.healthaffairs.org/do/10.1377/hblog20190920.981503/full/
- 176Joudrey PJ, Chadi N, Roy P, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug Alcohol Depend. 2020; 27:107968.
- 177Goffman E. Stigma: Notes on the management of a spoiled identity. Englewood Cliffs, NJ: Prentice-Hall, 1963.
- 178Pescosolido BA, Martin JK. The stigma complex. Annu Rev Sociol. 2015; 41: 87–116.
- 179Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: Associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017; 68(5): 462–469.
- 180Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014; 65(10): 1269–1272.
- 181 Legal Action Center. State Medicaid programs should follow the “Medicare Model”. 2019 [cited 2019 Sept]. Available from: https://lac.org/wp-content/uploads/2019/07/access-to-meds-in-medicaid-eweber-FINAL-070919.pdf
- 182 Narcotics Anonymous World Services. Narcotics Anonymous and persons receiving medication-assisted treatment. Chatsworth, CA: NA World Services, Inc., 2016 [cited 2019 Sept]. Available from: https://www.na.org/admin/include/spaw2/uploads/pdf/pr/2306_NA_PRMAT_1021.pdf.
- 183McGinty EE, Stone EM, Kennedy-Hendricks A, Barry CL. Stigmatizing language in news media coverage of the opioid epidemic: Implications for public health. Prev Med. 2019; 124: 110–114.
- 184Botticelli MP, Koh HK. Changing the language of addiction. JAMA. 2016; 316(13): 1361–1362.
- 185Ashford RD, Brown AM, Curtis B. Substance use, recovery, and linguistics: The impact of word choice on explicit and implicit bias. Drug Alcohol Depend. 2018; 189: 131–138.
- 186van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug Alcohol Depend. 2013; 131(1): 23–35.
- 187Collins AB, Bluthenthal RN, Boyd J, McNeil R. Harnessing the language of overdose prevention to advance evidence-based responses to the opioid crisis. Int J Drug Policy. 2018; 55: 77–79.
- 188 The American Pharmacists Association. Oath of a pharmacist. 1994 [cited 2019 Aug]. Available from: http://www.pharmacist.com/oath-pharmacist
- 189Bratberg J. Pharmacy: Addressing substance use in the 21st century. Subst Abuse. 2019; 40(4): 421–434.
- 190 American Association of Colleges of Pharmacy. Academic pharmacy's role in increasing knowledge, access to resources and evidence to combat the opioid epidemic, executive summary. 2019 [cited 2019 Aug]. Available from: https://www.aacp.org/opioid
- 191Lee M, Saseen JJ, Beckman E, et al. Expanding the pharmacist's scope of practice at the state level: Support for board certification within the credentialing process. J Am Coll Clin Pharm. 2019; 2(6): 694–701.
- 192 American Society of Health-System Pharmacists Online residency directory. 2019 [cited 2019 Nov]. Available from: https://accreditation.ashp.org/directory/#/program/residency
- 193 Centers for Medicare & Medicaid Services. Trump administration takes steps to expand access to treatment for opioid use disorder. 2019 [cited 2019 Nov]. Available from: https://www.cms.gov/newsroom/press-releases/trump-administration-takes-steps-expand-access-treatment-opioid-use-disorder
- 194Nagel, LM. Drug enforcement administration emergency narcotic addiction treatment. 2002 [cited 2020 Sept]. Available from: https://www.deadiversion.usdoj.gov/pubs/advisories/emerg_treat.htm
- 195 Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. HHS publication no. (SMA) 18-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018 [cited 2020 Mar]. Available from: https://store.samhsa.gov/product/SMA18-5063FULLDOC.
- 196Cueva JP, Roche C, Ostovar M, et al. C7β-methyl analogues of the orvinols: The discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. J Med Chem. 2015; 10: 4242–4249.
- 197Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008; 2(suppl): S133–S153.